Dec 10, 2018
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
Dec 03, 2018
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX® Genomic Prostate Score® Test
Nov 29, 2018
New Analysis of NSABP Randomized B-20 Study Confirms Patients with Oncotype DX Breast Recurrence Score® Results Greater Than 25 Have Life-saving Substantial Benefit from Chemotherapy, Reinforcing the Conclusions of the Landmark TAILORx Study
Nov 19, 2018
Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test
Nov 06, 2018
Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance
Oct 30, 2018
Genomic Health to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
Oct 29, 2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Oct 22, 2018
Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX® Tests in Guiding Treatment for Breast and Prostate Cancer Patients
Oct 09, 2018
New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment
Sep 12, 2018
Epic Sciences Announces Completion of $52 Million Series E Financing
Sep 07, 2018
German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Aug 02, 2018
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
Jul 26, 2018
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
May 30, 2018
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
May 21, 2018
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score(TM) Test in Guiding Treatment Decisions
May 09, 2018
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
May 02, 2018
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
Apr 26, 2018
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 25, 2018
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
Mar 30, 2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect(TM) Test in Patients with Metastatic Castration-Resistant Prostate Cancer